Collaboration and License Agreement between Ionis Pharmaceuticals, Inc. and Novartis Pharma AGCollaboration and License Agreement • November 2nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of August 2, 2023 (the “Execution Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad CA 92010 USA (“Ionis”), and Novartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Novartis and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices, schedules, and exhibits are a part of this Agreement.
Research, Development, and License Agreement Among Ionis Pharmaceuticals, Inc., And And Hoffmann-La Roche Inc.Research, Development, and License Agreement • November 2nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This RESEARCH, DEVELOPMENT, AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 26th day of September, 2023 (the “Effective Date”) by and among Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Ionis”), F. Hoffmann-La Roche Ltd, a Swiss corporation, having its principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., a New Jersey corporation, having its principal place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424 (“Roche US”; Roche Basel and Roche US are collectively referred to as “Roche”). Roche and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
AMENDED AND RESTATED LEASE AGREEMENT DATED AS OF AUGUST 21, 2023 Between LOTS 21 & 22 OWNER (DE) LLC a Delaware limited liability company AS LANDLORD and IONIS PHARMACEUTICALS, INC., a Delaware corporation AS TENANTLease Agreement • November 2nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Amended and Restated Lease Agreement (this “Lease”), dated as of August 21, 2023 (the “Effective Date”), is made between Lots 21 & 22 Owner (DE) LLC, a Delaware limited liability company (“Landlord”), and Ionis Pharmaceuticals, Inc., a Delaware corporation (“Tenant”). Landlord and Tenant are parties to a Lease Agreement dated August 21, 2023 (the “Original Lease”), which Original Lease is being amended and restated in its entirety on this September 25, 2023 (the “A&R Effective Date”), to reflect certain modifications to the scope of Landlord’s Construction Work and Tenant Improvements (each as defined herein). As of the A&R Effective Date, the Original Lease shall be of no further force and effect and shall be superseded in its entirety by this Lease.
